From the archive. This pick came before our first emailed issue. We wrote it on Nov 3, 2026 from sources published around that day, with the same checks as every issue. It isn't part of the track record.
The pick
Option Care Health (OPCH) had the biggest jump in trading volume compared with its usual level. Volume was 32.8x its 30-day average, and the stock rose 32.65%.
What happened
On October 6, 2026, Option Care Health, CD&R and McKesson announced a definitive agreement. CD&R and McKesson will acquire Option Care Health for $32.05 per share. The deal reflects a total enterprise value of about $5.8 billion.
The price is a premium of about 37% to the October 5, 2026 closing share price. CD&R will hold a majority interest of about 51%. McKesson will invest about $1.4 billion for a minority interest of about 49%.
The deal is expected to close in the first half of calendar year 2027. It is subject to customary closing conditions, including approval by Option Care Health's stockholders and required regulatory approvals. After closing, the stock will no longer be listed on Nasdaq, and the company will become privately held.
Option Care Health's board unanimously concluded the transaction maximizes value for stockholders. The company also withdrew its previously disclosed financial guidance.
Source: [SEC filing]
What news reports said
Yahoo Finance, citing StockStory, reported that shares jumped 33.2% in the pre-market session after the Financial Times reported that McKesson and Clayton Dubilier & Rice were nearing a deal valued at more than $5 billion. [Yahoo Finance]
Benzinga reported on October 6 that the stock was trading below the deal price, in an article about the spread. [Benzinga]
The numbers
- Previous close: $23.37
- Close: $31.00
- Change: +32.65%
- Volume: 65,081,906
- 30-day average volume: 1,984,904
- Volume multiple: 32.8x
- Behind the move: a company press release
What to watch
- Option Care Health expects to release third quarter results on November 4, 2026. It will not host a live conference call.
- The deal is expected to close in the first half of calendar year 2027, pending stockholder and regulatory approvals.
Source: [SEC filing]
More coverage
What happened next
Measured from this day's close. Shown for every pick, good or bad. See the full track record.